Study identifier:D9617C00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A randomized double-blind placebo-controlled study to assess the prevention of low-dose acetylsalicylic acid (ASA) associated gastroduodenal lesions and upper gastrointestinal symptoms in patients taking esomeprazole 20 mg once daily for 26 weeks.
Gastroesophageal Reflux
Phase 3
No
Esomeprazole
All
960
Interventional
60 Years - 100 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of the study is to evaluate the effect of esomeprazole 20 mg od versus placebo for the prevention of gastric and/or duodenal ulcers in patients taking low-dose ASA.
Location
Location
Bondi Junction, NSW, Australia
Location
Bracken Ridge, QLD, Australia
Location
Carina Heights, QLD, Australia
Location
Adelaide, SA, Australia
Location
ASHFORD, SA, Australia
Location
Wayville, SA, Australia
Location
Woodville, SA, Australia
Location
Ballarat, VIC, Australia
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.